234 results about "Phosphatine" patented technology

The present invention provides a system for enhancing clearance or destruction of undesirable cells or noncellular molecular entities by tagging such cells or noncellular molecular entities with a marker that targets the cells or noncellular molecular entities for phagocytosis (phagocytic marker). The target cells can be, for example, endothelial cells, tumor cells, leukocytes, or virus-infected cells. In certain embodiments of the invention the tagging is accomplished by administering a composition comprising an antibody or ligand linked to the phagcytotic marker, wherein the antibody or ligand binds to a cell type specific marker present on or in the cell surface of a target cell. In preferred embodiments of the invention, the phagocytic marker comprises phosphatidylserine or a group derived from phosphatidylserine, thrombospondin-1, annexin I, or a derivative of any of these.

Provided are compounds according to Formula (I):or stereoisomer, prodrug, polymorph, or pharmaceutically acceptable salt forms thereof, wherein X, Y, R1, R6, R7, and R8 are as defined, and which compounds are effective inhibitors of PI3-kinase and / or other medically and clinically relevant kinases. Also provided are pharmaceutical compositions and methods of using the compounds and compositions as PI3-kinase and kinase inhibitors. More particularly, the compounds of the invention provide treatments and therapeutics for human diseases regulated by, or associated with, the activity of, PI3-kinases and / or protein kinases, or mutant or variant forms thereof.

Disclosed are new phosphatidylserine binding constructs with surprising combinations of properties, and a range of diagnostic and therapeutic conjugates thereof. The new constructs effectively bind phosphatidylserine targets in disease and enhance their destruction, and can also specifically deliver attached imaging or therapeutic agents to the disease site. Also disclosed are methods of using the new construct compositions, therapeutic conjugates and combinations thereof in tumor vasculature targeting, cancer diagnosis and treatment, and for treating viral infections and other diseases.

Medicinal compositions which are useful as phosphatidylinositol 3-kinase (PI3K) inhibitors and anticancer agents; and novel bicyclic or tricyclic condensed heteroaryl derivatives or salts thereof having favorable effects of inhibiting PI3K and suppressing the proliferation of cancer cells.

The invention relates to a stable preparation of phosphatidylserine and a preparation method, application as well as an application product of the stable preparation. The preparation method comprises the following step of processing the phosphatidylserine through microencapsulation, micro-pelletization or liposome encapsulation. The stable preparation of the phosphatidylserine can be independently applied as a medicine or can be added into daily foods, drinks and health-care products, also has an important effect on health care of brains while guaranteeing the color and the taste of the daily foods and the drinks of people and is of great benefit to brain disorder such as nutritional supplement of brain development of students, overstrain of nerves of the adults, and memory loss, brain atrophy and senile dementia of the middle aged and elderly people.

The invention discloses a metabonomics-based diagnosis marker for chronic obstructive pulmonary disease and application thereof. The diagnosis marker comprises the following 28 blood plasma metabolismmarkers: phosphatidylcholine PC 16:1-36:3, phosphatidylcholine PC 26:0-22:4, phosphatidylcholine PC 26:0-22:3, phosphatidylcholine PC 47:5e, phosphatidylcholine PC 44:11e, phosphatidylcholine PC 16:0-24:5, phosphatidylcholine PC 20:2-20:3, phosphatidylcholine PC 40:10, phosphatidylcholine PC 38:9e, phosphatidylcholine PC 18:1-20:4, phosphatidylcholine PC 16:0-20:3, phenylacetaldehyde, dihydrouracil, nicotinamide, 4-methoxycinnamic acid, ketovaline, threonine, DL-3-aminoisobutyric acid, pyruvic acid, stachyose, caffeic acid, N, N-dimethylaniline, maltotriose, D(-)-gulonate-gamma-lactone, and L-asparaginase. The marker provided by the invention has good classification on metabolome data of patients suffering chronic obstructive pulmonary disease and healthy people, and can accurately distinguish the patients suffering chronic obstructive pulmonary disease from the healthy people.

A food item, preferably a bar of chocolate, that has a phosphatidyl serine content of 100 mg to 300 mg and a relatively high carbohydrate content.

The disclosure provides compositions treating traumatic brain injuries such as concussions. In one embodiment, the composition comprises phosphatidylserine, phosphatidylcholine, quercetin, astaxanthin, R-alpha lipoic acid, N-acetyl cysteine, taurine, L-glutamine, carnitine, D-ribose, creatine, epigallocatechin gallate, melatonin, ginkgo leaf extract, curcumin and L-glycine. The disclosure also provides methods for treating traumatic brain injuries such as concussions by administering an effective amount of the compositions described within.

A mixed forage for the later-phase larvae of scylla is prepared proportionally from protein, fat, fibers, Ca, P, and phosphatide through pulverizing, sieving, mixing, adding peptone, fish slurry and edible oil, mixing, modifying, granulating, drying and cooling.

The invention discloses new application of a 2-(4-fluorophenyl)-3-nitro-8-O-ethyl-2-hydro-benzopyran compound, in particular application of the compound serving as phosphatidylinositol-3-kinase (PI3K) inhibitor. The PI3K inhibitor can inhibit PI3K and disturb a PI3K / AKT signal channel, has good treatment effect on multiple tumors, particularly malignant hematological diseases, can effectively control the propagation of tumor cells and induce the apoptosis thereof, and has the effect of inhibiting and treating the tumors; and meanwhile, the PI3K has low toxicity.

The present invention provides a system for enhancing clearance or destruction of undesirable cells or noncellular molecular entities by tagging such cells or noncellular molecular entities with a marker that targets the cells or noncellular molecular entities for phagocytosis (phagocytic marker). The target cells can be, for example, endothelial cells, tumor cells, leukocytes, or virus-infected cells. In certain embodiments of the invention the tagging is accomplished by administering a composition comprising an antibody or ligand linked to the phagcytotic marker, wherein the antibody or ligand binds to a cell type specific marker present on or in the cell surface of a target cell. In preferred embodiments of the invention, the phagocytic marker comprises phosphatidylserine or a group derived from phosphatidylserine, thrombospondin-1, annexin I, or a derivative of any of these.

The invention relates to an oral solid preparation containing polyene phosphatidyl choline and a preparation method thereof. The oral solid preparation comprises polyene phosphatidyl choline as a raw material, antioxidants and related accessories necessary for corresponding forming of the preparation. The procedure is as follows: cryogenically comminuting and sieving the polyene phosphatidyl choline, and then pelletizing, granulating and drying under reduced pressure; then adding accessories for the corresponding preparation, thereby obtaining the corresponding oral solid preparation according to the procedure for corresponding forming of the preparation. The finished preparation is convenient for clinical using and has good material liquidity for production and preparation, which leads to an easy operated forming process of corresponding preparation formation with good quality control.

The invention discloses a metabonomics-based application of endogenous small-molecular substances in rapid detection of hepatotoxicity. The endogenous small-molecular substances are 12 hepatotoxicity biomarkers, i.e., L-alanine, L-phenylalanine, L-carnitine, L-carnitine palmitoyl, tryptophan, arachidonate, cholic acid, lysophosphatidylcholine (14:0), lysophosphatidylcholine (16:1), lysophosphatidylcholine (18:2), lysophosphatidylcholine (20: 3) and hemolysis phosphatidyl ethanolamine (18:2); and the endogenous small-molecular substances also refers to 3 special hepatotoxicity biomarkers, i.e. L-carnitine, cholic acid and lysophosphatidylcholine (14:0). By adopting the hepatotoxicity biomarkers, the discovery and diagnosis of the liver injury can be earlier than those of the existing biochemical detection indexes, the hepatotoxicity biomarkers can be well used for preventing, discovering and treating the hepatotoxicity, the limitation of the existing indexes can be overcome, and accurate detection information can be provided in time.

The invention relates to a method for preparing snake oil nanometer micro capsule emulsion, wherein it is formed by snake oil, phosphatide, surface activator, oxidization resistance, and dispersing medium; the production comprises that: mixing phosphatide, snake oil and surface activator; mixing mixture with disperse medium; treating with high-pressure uniform machine. The average diameter is lower than 100nm, as transparent dense liquid; it has stable quality, to reduce smell; and it has high solubility, to be matched with cosmetic freely.

The present invention refers to the renin / prorenin receptor (RER) signal transduction pathway and, in particular, to the role of promyelocytic zinc finger protein (PLZF) and its downstream targets involved in this pathway, e.g. the p85α subunit of phosphatidylinositol-3 kinase (PI3K-p85α). In more detail, the present invention refers to a method for determination of RER activity, e.g. stimulation or inhibition of RER activity, using PLZF activity as a measurement from which RER activity is derived. For the determination of RER activity, use can be made of RER / PLZF protein interaction, PLZF translocation and / or PLZF recruitment. The present invention further refers to a use of said method for identifying RER ligands, e.g. pharmaceutically active agonists or antagonists, as well as for studying undesired side-effects of renin inhibitors.

The present invention provides methods for identifying agents that increase lifespan and increase resistance to oxidative and / or electrophilic stress. Also provided are methods for identifying biomarkers of longevity or identifying pathways governing longevity in response to phosphatidylinositol 3,4,5-triphosphate signaling.

The administration of nutritional supplements such as phosphatidylcholine; linoleic acid and alpha linoleic acid in an approximately 4:1 (v / v) ratio; and mineral supplements provides an effective method for the treatment of ALS. Subjects presenting with symptoms indicative of ALS can therefore be treated with these nutritional supplements to inhibit progression of ALS. Subjects at risk for developing ALS can also be treated with these nutritional supplements to delay the onset of ALS symptoms.

The invention relates to a high-performance liquid chromatography of phosphatidylserine. The High-performance liquid chromatography comprises the steps of (1) preparing a phosphatidylserine standard solution, and using a chloroform-methanol solution to dissolve and fix the constant volume to be 80 to 400ug / ml; (2) preparing a phosphatidylserine sample solution, using the chloroform-methanol solution to dissolve and fix the volume, and diluting and preparing the sample solution of which the phosphatidylserine content is within the concentration range of standard serial solutions; (3) measuring the standard solution and the sample solution under the condition that the high-performance liquid chromatography cooperates with an evaporative light-scattering detector, performing logarithmetics on the peak area of the standard solution as a y-coordinate, performing logarithmetics on the concentration of the standard solution as an x-coordinate, drawing a double logarithmic standard curve, and finding the concentration of the sample solution from the double logarithmic standard curve according to the peak area. The high-performance liquid chromatography has the following beneficial effects: due to the fact that the high-performance liquid chromatography cooperates with the evaporative light-scattering detector, a simple and effective method is provided for the quality control during a phosphatidylserine production process through the entering of different mobile phase volume ratios.

A process for preparing the high-purity (more than 96%) vegetative phosphatidylinositol (PI) from soybean includes such steps as extracting in solvent, separating, and purifying by macroreticular resin chromatography. Said PI has high activity of selectively killing more kinds of human cancer cells and preventing and treating senile dementia.

The invention discloses a receipt of gypenoside lipidosome consisting of sterol. The receipt comprises gypenoside, a phosphatide material and the sterol. The invention further discloses a preparation method of the gypenoside lipidosome consisting of the sterol. A preparation form of the lipidosome can be a freeze-drying injection, an injection, a transdermal preparation, aerosol, oral liquid, a solution, an eye-drops preparation, a tablet or a capsule. The gypenoside lipidosome has important treatment effects for hyperlipidemia and cardiovascular and cerebrovascular diseases, and furthermore, has positive treatment and prevention effects for tumor, hepatitis, gastritis, gastric and duodenal ulcer, gastroptosis, stomatitis, diabetes mellitus, astriction, haemorrhoids, asthma, cephalagra, acne, stain, gall-stone, numbness of limbs, pachulosis, male infertility, recession of sexual functions, fatness, white hair and baldness. Furthermore, the physical strength of a human body can be enhanced, the immunity of the organism is improved, the state of fatigue can be relieved, the sleep quality can be obviously improved, the appetite can be whetted, and the senescence can be delayed.

The invention discloses a complete humanized antibody which is selected from humanized high-capacity phage antibody library and is high-affinity-combined with phosphatidylinositol proteoglycan 3. The invention includes a selection method of the antibody, an antibody coding sequence and corresponding amino acid residue sequence, and especially includes three CDR-zone sequences respectively at a heavy chain and a light chain, combination characters of an antigen and the construction method of the complete antibody. The antibody is a complete humanized antibody, is used for treatment in human body, is low in immunogenicity, is less in toxic and side effects, and has a potential value of treating liver cancer and melanin tumor.

The invention relates to a SN38 lipid composition, and a preparation method and application thereof. The SN38 lipid composition comprises SN38, phosphatide, oil for injection, cholesterol, a long-circulating film material, a functional material capable of forming a protection layer on the surface of lipid, and a functional adjuvant capable of reversing drug resistance. The SN38 lipid composition overcomes the problems that drugs are poor in solubility and hard to prepare preparations, that conventional lipid preparations are low in entrapment rate and poor in in-vitro stability, that drugs areprone to rapid leakage and the like in the prior art; and the SN38 lipid composition improves the in-vivo circulation time of drugs, has a certain targeting function, allows drugs to be enriched at tumor sites, reduces toxic and side effect, substantially enhances drug effect, and can overcome the multidrug resistance of tumors to a certain degree.

A yolk lecithin capsule is prepared from yolk lecithin 100 (wt. portions), vegetative oil 100-150, VE3, and tert-butylhydroquinone 0.03 as antioxidizing agent. Its advantages are no need of cold-chain transportation, and high content of phosphatidylcholine and linolenic acid.

The invention relates to a lipid gel medicinal preparation, a preparation method and a purpose. The lipid gel medicinal preparation comprises PEGylated phosphatide, non-PEGylated phosphatide, an active substance with effective treatment amount and a solvent, wherein the solvent contains water or physiological aqueous medium. The preparation method comprises the following steps: i) preparing an active substance solution; ii) mixing the above active substance solution with PEGylated phosphatide, non-PEGylated phosphatide, the solvent and other pharmaceutically acceptable accessory with a prescription amount; and iii) heating and mixing a solution obtained in the step ii), and fully swelling. The invention also comprises an application of the lipid gel in a slow release drug delivery system. The preparation has high maximum drug loading, is suitable for large scale production, and has the advantages of simple preparation method, low toxicity and obvious slow release effect.

A doxycycline hydrochloride liposome with high optical and thermal stability, high power to pass through skin and mucosa, and high antibacterial effect is prepared from phosphatide, cholesterol, doxycycline hydrochloride and emulsifier by film dispersing method, injection method, or reverse evaporation method.

The invention discloses a breast cancer-related kinase mutation detection panel. The detection panel comprises receptor tyrosine kinase (RTK), phosphatidylinositol 3-kinase (PI3K), mitogen-activated protein kinase (MAPK) related genes, and an exon region and a part of intronic regions of a downstream gene. The invention further discloses a kit containing the detection panel. The detection panel can detect gene mutation guiding diagnosis and treatment more efficiently, is of great significance to clinical diagnosis and discovery of a target spot of target treatment, and can help lower gene detection cost of patients.

The present invention belongs to the field of medicine preparation technology, relates to medicine preparation for treating several kinds of liver and gallbladder diseases and its preparation, and is especially one kind of polyene phosphatidyl chloine infusion solution and its preparation process. The preparation process of the polyene phosphatidyl chloine infusion solution includes: adding polyene phosphatidyl chloine, co-solvent, pH regulator, antioxidant and other supplementary material into injection water; regulating pH value to 6.5-10.0; adding active carbon and filtering, adding vitamins to obtain intermediate; content meat, filtering with 0.1-0.45 micron membrane and packing. The stability test shows that the preparation process is stable and feasible; and the safety test shows that the polyene phosphatidyl chloine infusion solution has no allergic reaction, no hemolysis effect, and no irritation on blood vessel.

The invention discloses phosphatidylserine pressed candy and a production process thereof. The phosphatidylserine pressed candy is prepared from raw materials in parts by weight as follows: 285-315 parts of phosphatidylserine, 185-215 parts of soybean lecithin, 3-7 parts of hydroxypropyl methylcellulose, 460-480 parts of isomaltitol, 8-12 parts of silicon dioxide and 9-21 parts of magnesium stearate through pre-treatment, weighing, mixing, granulation, drying, pressing and packaging processes. The phosphatidylserine pressed candy has the advantages that the efficacy of improving nerve cells, improving memory and the like can be realized through scientific matching and the synergetic function of multiple raw materials, and the candy is safe, has no side effects, is convenient to eat and has better market application prospect.